GlassScriptPhysician profile
Jennifer Goodin
NPI 1174129381
$2,092.21
in general payments reported to CMS, 2019-2025
28 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $668 · 2022: $917 · 2023: $273 · 2024: $111 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $507.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.07 | 2021-2023 | Stiolto Respimat |
| Novo Nordisk INC | $284.93 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $215.33 | 2021-2024 | |
| Amarin Pharma, INC. | $185.08 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $157.55 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $103.22 | 2021 | |
| Glaxosmithkline, LLC. | $100.12 | 2022-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $78.77 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.54 | 2021-2023 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $62.90 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.81 | 2022-2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $56.18 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $49.47 | 2022-2023 | Nuzyra |
| Pfizer INC. | $44.66 | 2021-2023 | |
| Exact Sciences Corporation | $40.54 | 2025 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $39.58 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $39.46 | 2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $33.41 | 2022 | |
| Edwards Lifesciences Corporation | $25.49 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Idorsia Pharmaceuticals US INC | $22.42 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.46 | 2022 | |
| Lundbeck LLC | $21.32 | 2022 | |
| Orexo US, INC. | $20.92 | 2025 | Zubsolv |
| Novartis Pharmaceuticals Corporation | $19.60 | 2022 | |
| Merck Sharp & Dohme LLC | $14.89 | 2021 | |
| Medtronic, INC. | $14.45 | 2023 | Minimed 770g |
| Teva Pharmaceuticals USA, INC. | $13.50 | 2024 | Austedo Xr |
| Eisai INC. | $12.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Goodin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.